Cargando…
Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?
Cancer therapy remains a challenge due to toxicity limitations of chemotherapy and radiation therapy. Oncolytic viruses that selectively replicate and destroy cancer cells are of increasing interest. In addition to direct cell lysis, these vectors stimulate an anti-tumor immune response. A key regul...
Autores principales: | Denton, Nicholas L., Chen, Chun-Yu, Scott, Thomas R., Cripe, Timothy P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344259/ https://www.ncbi.nlm.nih.gov/pubmed/28536380 http://dx.doi.org/10.3390/biomedicines4030013 |
Ejemplares similares
-
Immune System, Friend or Foe of Oncolytic Virotherapy?
por: Filley, Anna C., et al.
Publicado: (2017) -
Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy
por: Mamola, Joseph A., et al.
Publicado: (2023) -
Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment
por: Denton, Nicholas L., et al.
Publicado: (2018) -
The Multifaceted Role of Macrophages in Oncolytic Virotherapy
por: Hofman, Laura, et al.
Publicado: (2021) -
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity
por: Leddon, Jennifer L, et al.
Publicado: (2015)